Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Berman
B A
BA
Ross
R N
RN
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000787:Angina Pectoris / Q000188:drug therapy; D001250:Asthma, Exercise-Induced / Q000188:drug therapy; D001986:Bronchial Spasm / Q000139:chemically induced; D002118:Calcium / Q000502:physiology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D004110:Diltiazem / Q000009:adverse effects / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D007473:Ion Channels / Q000502:physiology; D008171:Lung Diseases / Q000150:complications / Q000188:drug therapy*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D007473:Ion Channels; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D002118:Calcium